These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12701297)

  • 1. [Diagnostic use of SPECT with visualization of dopamine transporters in Parkinson disease. The Danish Society of Neurology].
    Løkkegaard A; Friberg L
    Ugeskr Laeger; 2003 Mar; 165(12):1247. PubMed ID: 12701297
    [No Abstract]   [Full Text] [Related]  

  • 2. [Functional imaging of neuroreceptors in parkinsonism].
    Knudsen GM
    Ugeskr Laeger; 2002 Apr; 164(17):2259-62. PubMed ID: 11989173
    [No Abstract]   [Full Text] [Related]  

  • 3. Images in neuroscience. Neuroimaging, XII. SPECT imaging of dopamine nerve terminals.
    Seibyl JP; Marek K; Innis RB
    Am J Psychiatry; 1996 Sep; 153(9):1131. PubMed ID: 8780413
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine receptors in Parkinson's disease: imaging studies.
    Stoessl AJ; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():65-71. PubMed ID: 12442664
    [No Abstract]   [Full Text] [Related]  

  • 5. [Positron-emission tomographic studies of the brain in parkinsonism patients].
    Berezhkova LV
    Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(6):93-7. PubMed ID: 8788992
    [No Abstract]   [Full Text] [Related]  

  • 6. [Functional neuroimaging in movement disorders].
    Borbély K
    Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
    de Natale ER; Niccolini F; Wilson H; Politis M
    Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease.
    Booij J; Knol RJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S425-8. PubMed ID: 18267276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
    Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
    J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional imaging of neurotransmitter systems in movement disorders.
    Ilgin N
    Q J Nucl Med; 1998 Sep; 42(3):179-92. PubMed ID: 9796366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of radiotracer imaging in Parkinson disease.
    Zweig RM; Lilien DL; Tainter K; Patterson J
    Neurology; 2005 Oct; 65(7):1144-5; author reply 1144-5. PubMed ID: 16220586
    [No Abstract]   [Full Text] [Related]  

  • 13. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients].
    Hierholzer J; Cordes M; Schelosky L; Barzen G; Poewe W; Henkes H; Keske U; Horowski R; Felix R
    Rofo; 1992 Oct; 157(4):390-8. PubMed ID: 1391843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive in vivo imaging of transplant function.
    Brooks DJ; Piccini P
    Prog Brain Res; 2000; 127():321-32. PubMed ID: 11142033
    [No Abstract]   [Full Text] [Related]  

  • 16. Physiologic modeling of PET data: quantitative conflict and challenge.
    Ichise M; Ballinger JR
    J Nucl Med; 1997 Aug; 38(8):1266-7. PubMed ID: 9255162
    [No Abstract]   [Full Text] [Related]  

  • 17. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease.
    Hwang WJ; Yao WJ; Wey SP; Ting G
    J Nucl Med; 2004 Feb; 45(2):207-13. PubMed ID: 14960637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional kinetics of [11C]methylspiperone in the brain studied by positron emission tomography in patients with Parkinson's disease.
    Hägglund J; Aquilonius SM; Bergström K; Eckernäs SA; Hartvig P; Lundqvist H; Långström B; Malmborg P; Någren K
    Adv Neurol; 1987; 45():99-101. PubMed ID: 2950732
    [No Abstract]   [Full Text] [Related]  

  • 19. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical impact of cerebral dopamine-D2 receptor scintigraphy].
    Larisch R; Klimke A
    Nuklearmedizin; 1998; 37(7):245-50. PubMed ID: 9830615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.